Eskandarieh, S., Moghadasi, A. N., Sahraiain, M. A., Azimi, A. R., & Molazadeh, N. (2019). Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder. Iranian Journal of Neurology, 18(3), 93–98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858599/.
Miao, J., Aboagye, D. E., Chulpayev, B., Liu, L., Ishkanian, G., Kolanuvada, B., Alaie, D., & Petrillo, R. L. (2018). Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case. The American Journal of Case Reports, 19, 41–46. https://doi.org/10.12659/AJCR.906150.
Neuromyelitis Optica Spectrum Disorder. (n.d.). NORD (National Organization for Rare Disorders). Retrieved July 9, 2021, from https://rarediseases.org/rare-diseases/neuromyelitis-optica/.
Neuromyelitis optica—Symptoms and causes. (n.d.). Mayo Clinic. Retrieved July 9, 2021, from https://www.mayoclinic.org/diseases-conditions/neuromyelitis-optica/symptoms-causes/syc-20375652.
Tillema, J. M., & McKeon, A. (2012). The spectrum of neuromyelitis optica (NMO) in childhood. Journal of Child Neurology, 27(11), 1437–1447. https://doi.org/10.1177/0883073812451495.
Miyamoto, K., Minamino, M., Kuwahara, M., Tsujimoto, H., Ohtani, K., Wakamiya, N., Katayama, K. I., Inoue, N., & Ito, H. (2023). Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. Frontiers in immunology, 14, 1090548. https://doi.org/10.3389/fimmu.2023.1090548